Board of Directors


Alan C. Nelson, PhD – Chairman of the Board

Dr. Nelson, is founder, chairman and CEO of VisionGate®. He is a physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. He is former Executive Director of Arizona State University’s (ASU) Biodesign Institute and has held faculty positions at ASU, University of Washington, MIT and Harvard. Dr. Nelson holds more than 100 US patents and has more than 100 peer-reviewed publications in the field of biomedical imaging.

Robert A Heft, PhD – Board Director

Robert Heft, Ph.D., has served on the VisionGate Board of Directors since 2015. Dr. Heft is former CEO and member of the Board of Directors of Enobia Pharma Inc. In 2012, he sold Enobia to Alexion Pharmaceuticals Inc. for $1.1 Billion, one of the largest-ever sales of a private, pre-commercial biopharmaceutical company. Dr. Heft currently serves on the boards of Zingenix Ltd., Ra Pharmaceuticals, Inc., Lumos Pharma, Inc., Clementia Pharmaceuticals, Inc and Parvus Therapeutics, Inc. He also serves on the Advisory Board of Sectoral Asset Management. Dr. Heft received a Ph.D. from the Massachusetts Institute of Technology in Genetic Engineering and Radiological Sciences.

Walter Robb, PhD – Board Director

Dr. Robb is currently a management consultant and president of Vantage Management, Inc. He serves on the board of Mechanical Technology, Inc., eight private, start-up companies and is a former Celgene board member. He previously served as senior vice president for General Electric’s Corporate Research and Development center, one of the world’s largest and most diversified industrial laboratories, and served on the company’s Corporate Executive Council. Additionally, he headed GE Medical Systems for 13 years.

Maria Forero, MPH – Board Director

Ms. Forero is founder and principal of Ridgetop Health, the life sciences private equity arm of Ridgetop Capital Partners, a $500 million AUM investment firm. Prior to Ridgetop, Maria spent ten years at Novartis in numerous senior management roles across geographies and divisions including Head of Sales & Marketing for Sandoz Latin America and General Manager of Spain & Portugal for Novartis Vaccines. Before Novartis, Ms. Forero was a VP at Morgan Stanley and an Audit Manager at PricewaterhouseCoopers in London. She holds a Masters of Public Health from Columbia University, New York and a BSc in Human Genetics, from the University College London, UK.

Paul Kelly, MBA – Board Director

Mr. Kelly has been an analyst, consultant and investor in the biotechnology sector for more than twenty years. He had extended and successful assignments as an equity analyst at many top-tier firms where his principal focus was the genomics, tools and diagnostics subsector of biotechnology. Subsequently, Mr. Kelly engaged in consulting for biotechnology companies, and for hedge funds. He currently manages his own investments, continues his consulting activities and serves on the Board of Relmada Therapeutics. Mr. Kelly holds an AB in Biochemistry from Brown University, he attended the University of Rochester School of Medicine, and received an MBA in Finance from the University of Rochester.


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2018 - VisionGate, Inc.